

Martina Kirchner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9300799/publications.pdf>

Version: 2024-02-01

40
papers

1,573
citations

361413
20
h-index

315739
38
g-index

40
all docs

40
docs citations

40
times ranked

2523
citing authors

#	ARTICLE	IF	CITATIONS
1	Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 251-265.	4.2	22
2	Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 8.e11-8.e18.	1.6	8
3	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 303-313.	2.8	15
4	The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients. <i>Gastroenterology</i> , 2022, 162, 907-919.e10.	1.3	27
5	Histological and Molecular Plasticity of ALK-positive Non-Small-Cell Lung Cancer under Targeted Therapy - a Case Report. <i>Journal of Physical Education and Sports Management</i> , 2022, , mcs.a006156.	1.2	5
6	The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. <i>European Journal of Cancer</i> , 2022, 170, 106-118.	2.8	15
7	Novel GATA6-FOXO1 fusions in a subset of epithelioid hemangioma. <i>Modern Pathology</i> , 2021, 34, 934-941.	5.5	27
8	Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199650.	3.2	24
9	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. <i>Oncotmunology</i> , 2021, 10, 1860586.	4.6	40
10	Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 477-482.	0.7	8
11	De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 640048.	2.8	4
12	Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field. <i>Lung Cancer</i> , 2021, 154, 131-141.	2.0	8
13	Testing <i>NTRK</i> testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 178-188.	2.8	52
14	<i>miRNA</i> profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the <i>miR-451a/ATF2</i> axis. <i>Journal of Pathology</i> , 2020, 252, 239-251.	4.5	18
15	Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal “Type Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 848-859.	3.0	7
16	Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the <i>NanoString nCounter</i> technology with targeted <i>RNA</i> sequencing. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 406-416.	2.8	10
17	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. <i>International Journal of Cancer</i> , 2020, 146, 3053-3064.	5.1	14
18	<i>NTRK</i> testing: First results of the <i>QuipaEQ</i> scheme and a comprehensive map of <i>NTRK</i> fusion variants and their diagnostic coverage by targeted <i>RNA</i> -based <i>NGS</i> assays. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 445-453.	2.8	27

#	ARTICLE	IF	CITATIONS
19	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer – Results from a prospective pilot study using a 37 gene panel. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e17-637.e27.	1.6	12
20	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. Journal of Clinical Investigation, 2020, 130, 2488-2495.	8.2	23
21	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. Cancers, 2019, 11, 1309.	3.7	32
22	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	1.1	69
23	Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. Cancers, 2019, 11, 124.	3.7	36
24	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	5.1	76
25	Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. International Journal of Cancer, 2019, 145, 2963-2973.	5.1	24
26	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: <i>in silico</i> and real-life analysis of three larger gene panels. International Journal of Cancer, 2019, 144, 2303-2312.	5.1	95
27	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. International Journal of Cancer, 2019, 145, 649-661.	5.1	85
28	Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	5.1	131
29	Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. Genes Chromosomes and Cancer, 2019, 58, 3-11.	2.8	14
30	Defining molecular risk in ALK+ NSCLC. Oncotarget, 2019, 10, 3093-3103.	1.8	35
31	Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. International Journal of Cancer, 2018, 143, 139-150.	5.1	129
32	<i>EML4-ALK</i> fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK ⁺ non-small cell lung cancer. International Journal of Cancer, 2018, 142, 2589-2598.	5.1	93
33	Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility. Genes Chromosomes and Cancer, 2018, 57, 70-79.	2.8	19
34	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. JCO Precision Oncology, 2018, 2, 1-13.	3.0	20
35	Implementing tumor mutational burden (TMB) analysis in routine diagnostics – a primer for molecular pathologists and clinicians. Translational Lung Cancer Research, 2018, 7, 703-715.	2.8	152
36	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology, 2018, 50, 703-710.	0.6	21

#	ARTICLE	IF	CITATIONS
37	Precision oncology based on omics data: The NCT Heidelberg experience. International Journal of Cancer, 2017, 141, 877-886.	5.1	133
38	Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma. Genes Chromosomes and Cancer, 2017, 56, 214-220.	2.8	8
39	Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3Kâ€“AKT pathway. Genes Chromosomes and Cancer, 2017, 56, 11-17.	2.8	27
40	Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report. Diagnostic Pathology, 2016, 11, 133.	2.0	8